BrainsWay Ltd. (BRSYF)

Market Cap	576.12M +182.0%
Revenue (ttm)	56.22M +29.4%
Net Income	8.76M +123.6%
EPS	0.22 +176.9%
Shares Out	n/a
PE Ratio	65.78
Forward PE	41.30
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	16.84
Previous Close	16.84
Day's Range	16.84 - 16.84
52-Week Range	5.49 - 16.84
Beta	0.15
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About BrainsWay

BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer’s disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson’s diseases. The company serves ...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2003
• Employees: 129
• Stock Exchange: OTCMKTS
• Ticker Symbol: BRSYF

Financial Performance

In 2025, BrainsWay's revenue was $52.23 million, an increase of 27.33% compared to the previous year's $41.02 million. Earnings were $7.58 million, an increase of 159.33%.

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error